Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study
/ Novel breakthrough: first molecule to modulate the fundamental mechanism ofT cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related ...